Receptors and pharmacodynamics
What a drug does to the body: receptor families, agonists and antagonists, potency and efficacy, dose-response curves, tolerance and the therapeutic index.
By the end of this page you should be able to
- Classify drug targets and describe the four main receptor superfamilies with an example of each.
- Define affinity, efficacy, potency, EC50, Emax and intrinsic activity.
- Draw and interpret graded log dose-response curves for full, partial and inverse agonists and for competitive and non-competitive antagonists.
- Distinguish graded from quantal dose-response relationships and define therapeutic index.
- Explain tachyphylaxis, tolerance, receptor up-regulation and spare receptors.
Drug targets
Most drugs act by binding a protein: receptors, ion channels (local anaesthetics block voltage-gated Na channels), enzymes (aspirin acetylates cyclo-oxygenase; neostigmine inhibits acetylcholinesterase) and transporters (SSRIs block SERT; digoxin inhibits Na/K ATPase). A few act without a protein target: osmotic agents such as mannitol, antacids, chelators and activated charcoal.
The four receptor superfamilies
- Ligand-gated ion channels (ionotropic): milliseconds. Nicotinic ACh receptor (five subunits, two alpha binding sites), GABA-A (Cl channel, the site of benzodiazepines, barbiturates and propofol), NMDA and AMPA glutamate receptors, 5-HT3.
- G protein-coupled receptors (metabotropic): seconds. Seven transmembrane helices. Gs raises cAMP via adenylyl cyclase (beta adrenoceptors, H2, D1); Gi lowers cAMP and opens K channels (alpha-2, M2, mu opioid, D2); Gq activates phospholipase C, generating IP3 (Ca release) and DAG (protein kinase C) (alpha-1, M1, M3, H1, V1).
- Kinase-linked receptors: minutes to hours. Single transmembrane domain with intracellular tyrosine kinase activity, or linked to it. Insulin receptor, growth factor receptors, cytokine receptors via JAK-STAT.
- Nuclear (intracellular) receptors: hours to days. Lipid-soluble ligands cross the membrane and the receptor acts as a transcription factor. Glucocorticoid, mineralocorticoid, thyroid hormone, vitamin D, PPAR-gamma.
Binding and response
Affinity is how tightly a drug binds, expressed as the dissociation constant KD (concentration occupying half the receptors at equilibrium; lower KD means higher affinity). Efficacy (intrinsic activity) is the ability to activate the receptor once bound: 1 for a full agonist, between 0 and 1 for a partial agonist, 0 for an antagonist and negative for an inverse agonist.
Potency is the dose needed for a given effect, read as EC50 (concentration producing 50% of the maximum). It depends on affinity and efficacy and on tissue factors. Emax is the maximal effect, the clinical meaning of efficacy. A more potent drug is not a better drug: fentanyl is far more potent than morphine, but both are full agonists with the same ceiling.
The occupancy idea (response proportional to receptors occupied) fails when there are spare receptors: in many tissues a maximal response needs only a fraction of receptors occupied, so EC50 is lower than KD. This is why an irreversible antagonist may shift the curve right before it depresses the maximum, and why the neuromuscular junction tolerates about 70% receptor blockade before twitch height falls.
Agonists and antagonists
- Full agonist: reaches the tissue maximum. Morphine at mu receptors; adrenaline at beta receptors.
- Partial agonist: submaximal even at full occupancy; in the presence of a full agonist it acts as an antagonist. Buprenorphine at mu receptors, which is why it can precipitate withdrawal in a person dependent on methadone or heroin.
- Inverse agonist: stabilises the inactive state of a constitutively active receptor, reducing basal activity. Many H1 and H2 "antagonists" behave this way.
- Competitive (surmountable) antagonist: binds reversibly at the agonist site; parallel right shift, Emax unchanged. Naloxone, atropine, rocuronium (overcome by more acetylcholine after neostigmine).
- Irreversible competitive antagonist: binds covalently; at first a right shift, then a fall in Emax once spare receptors are used up. Phenoxybenzamine at alpha receptors.
- Non-competitive antagonist: acts at a different (allosteric) site or downstream; depresses Emax. Ketamine is an uncompetitive channel blocker of the NMDA receptor.
- Physiological antagonism: two agonists acting on different receptors with opposing effects: adrenaline (beta-2, bronchodilates) against histamine (H1, bronchoconstricts) in anaphylaxis.
- Chemical antagonism: direct binding of drug to drug. Protamine neutralising heparin; sugammadex encapsulating rocuronium; digoxin Fab fragments.
Graded and quantal curves; therapeutic index
A graded curve plots the size of a response in one subject or tissue against log dose: sigmoid, with a near-linear middle segment between 20% and 80%. A quantal curve plots the proportion of a population showing an all-or-none response (asleep, dead, seizure-free) at each dose; its median is the ED50, and its spread reflects variability between individuals.
Therapeutic index = TD50 ÷ ED50 (in animals, LD50 ÷ ED50). Narrow-index drugs used in emergency care include digoxin, lithium, phenytoin, theophylline, aminoglycosides and warfarin; these need levels or close monitoring. The therapeutic window is the concentration range between effect and toxicity in patients.
Changing sensitivity
- Tachyphylaxis: rapid loss of response over minutes, for example ephedrine (depletes noradrenaline stores) and repeated nitrates.
- Tolerance: gradual loss over days to weeks, needing higher doses: receptor down-regulation, uncoupling, metabolic induction or physiological adaptation. Opioids, benzodiazepines, nitrates.
- Up-regulation: more receptors after chronic blockade or denervation; the basis of rebound tachycardia when a beta blocker is stopped and of the hyperkalaemic response to suxamethonium after burns, crush or denervation (extrajunctional receptors spread across the muscle membrane).
Answering pharmacodynamics questions
- Define before you describe: "Potency is the dose required to produce a given effect; efficacy is the maximal effect." Then draw.
- Label axes properly: response (% of maximum) against log dose, with EC50 marked.
- Use emergency drugs as examples: naloxone, buprenorphine, rocuronium and sugammadex, adrenaline and histamine.
Where marks are lost
- Equating potency with efficacy, or saying a more potent drug is more effective.
- Drawing a non-competitive antagonist as a right shift. It lowers the maximum.
- Forgetting that a partial agonist can be an antagonist when a full agonist is present.
- Mixing up the G proteins: alpha-1 is Gq, alpha-2 is Gi, beta is Gs.
Where this meets intensive care
- Prolonged catecholamine infusion downregulates and desensitises beta receptors, so the response to a fixed infusion wanes in sepsis and after cardiac surgery.
- A partial agonist such as buprenorphine can behave as an antagonist when a full agonist occupies the receptor, which matters for analgesia in ICU.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Define potency and efficacy and illustrate the difference with a graph and two drugs you use.
Show answer
- Potency: amount of drug needed for a given effect (EC50); efficacy: maximal effect achievable (Emax).
- Graph: response against log dose; a left shift is more potent; a higher plateau is more efficacious.
- Fentanyl is about 50 to 100 times more potent than morphine, but both are full mu agonists with similar Emax.
- Buprenorphine has high affinity but lower efficacy than morphine (partial agonist), so has a ceiling, at least for respiratory depression.
- 2.
Draw the effect of a competitive antagonist on an agonist dose-response curve. How does an irreversible antagonist differ?
Show answer
- Reversible competitive: parallel right shift, same Emax; surmountable by more agonist. Dose ratio rises with antagonist concentration (Schild).
- Irreversible: effectively removes receptors; with spare receptors there is first a right shift, then Emax falls once no reserve remains; recovery needs new receptor synthesis.
- Examples: naloxone (reversible), phenoxybenzamine (irreversible, used before phaeochromocytoma surgery).
- 3.
A man on high-dose methadone is given buprenorphine and becomes distressed and sweaty. Explain.
Show answer
- Buprenorphine is a mu partial agonist with very high affinity and slow dissociation.
- It displaces methadone (a full agonist) from mu receptors but activates them less: net fall in mu stimulation, so precipitated withdrawal.
- Hard to reverse with more full agonist because of buprenorphine affinity; managed symptomatically or with further buprenorphine to reach a plateau.
- High affinity also explains why large naloxone doses may be needed to reverse buprenorphine.
- 4.
Describe the signalling of a G protein-coupled receptor using the beta-1 adrenoceptor.
Show answer
- Seven transmembrane receptor; agonist binding changes conformation and activates heterotrimeric Gs (alpha subunit swaps GDP for GTP and dissociates).
- Gs alpha stimulates adenylyl cyclase, raising cAMP, which activates protein kinase A.
- PKA phosphorylates L-type Ca channels (more Ca entry, positive inotropy), phospholamban (faster SR Ca uptake, lusitropy) and affects pacemaker currents (chronotropy).
- Signal ends with GTP hydrolysis, cAMP breakdown by phosphodiesterase (milrinone inhibits PDE3), and receptor phosphorylation by GRKs with beta-arrestin binding (desensitisation).
- Amplification: one receptor activates many G proteins, each cyclase makes many cAMP.
- 5.
What is the therapeutic index? Name some narrow therapeutic index drugs you might meet in an emergency patient.
Show answer
- TD50 ÷ ED50 from quantal dose-response curves (LD50 ÷ ED50 in animal studies); a measure of safety margin.
- Limited: ignores the slopes of the curves and individual variability; the certain safety factor (LD1 ÷ ED99) is more conservative.
- Narrow: digoxin, lithium, phenytoin, theophylline, aminoglycosides, warfarin, carbamazepine.
- Relevance: interactions or renal impairment easily push levels into toxicity.
- 6.
Classify antagonism with an example of each from emergency practice.
Show answer
- Pharmacological competitive reversible: naloxone at mu receptors; flumazenil at the benzodiazepine site.
- Non-competitive: ketamine at NMDA (channel block).
- Physiological: adrenaline versus histamine in anaphylaxis; glucagon bypassing beta blockade via its own receptor.
- Chemical: protamine with heparin; sugammadex with rocuronium; digoxin-specific antibody fragments; chelation.
- Pharmacokinetic: activated charcoal reducing absorption; urinary alkalinisation increasing salicylate excretion.
- 7.
What are spare receptors? Where do they matter clinically?
Show answer
- A maximal response is produced when only a fraction of receptors is occupied; the rest are a reserve.
- Consequence: EC50 lower than KD; partial agonists can look like full agonists in tissues with a big reserve.
- Neuromuscular junction: about 70% of nicotinic receptors must be blocked before twitch falls and about 90% to 95% for complete block; a normal train-of-four does not mean no residual block.
- Irreversible antagonists shift curves right before depressing Emax.
- 8.
Why does suxamethonium cause dangerous hyperkalaemia in a patient a week after a major burn but not on the day of the burn?
Show answer
- Burns, denervation, crush and prolonged immobility up-regulate nicotinic receptors, including immature (fetal gamma subunit) and alpha-7 receptors that spread beyond the endplate.
- Suxamethonium opens all of them; K efflux from the whole muscle membrane can raise plasma K by several mmol/L, risking arrest.
- Up-regulation takes time, so risk develops from about 24 to 72 hours after injury and persists for months.
- Use rocuronium instead.
- 9.
Contrast tachyphylaxis and tolerance with examples.
Show answer
- Tachyphylaxis: rapid (minutes, after a few doses); ephedrine and other indirect sympathomimetics as stores of noradrenaline run out.
- Tolerance: gradual (days to weeks); opioids, benzodiazepines, nitrates (impaired bioactivation and oxidative stress, so a nitrate-free interval helps).
- Mechanisms: receptor desensitisation, internalisation, down-regulation, enzyme induction (pharmacokinetic tolerance) and physiological compensation.
Practise this week
- First Part MCQs: pharmacology
- First Part SAQs, marked part by part
- First Part cross-table vivas
- Viva Examiner: practise answering aloud
Week 1 in the other subjects
- Physiology: Cell membranes, transport and body fluids
Not affiliated with the CICM. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.